LABORATORY SAFETY OF DUPILUMAB AND ITS EFFECT ON INFLAMMATORY BIOMARKERS IN ADULT CHINESE PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND PHASE III STUDY

被引：0

作者：

Zhao, Yan ^{[1
]}

Wu, Liming ^{[2
]}

Lu, Qianjin ^{[3
]}

Gao, Xinghua ^{[4
]}

Zhu, Xiaohong ^{[5
]}

Yao, Xu ^{[6
]}

Li, Linfeng ^{[7
]}

Li, Wei ^{[8
]}

Ding, Yangfeng ^{[9
]}

Song, Zhiqiang ^{[10
]}

Liu, Lingling ^{[11
]}

Dang, Ningning ^{[12
]}

Zhang, Chunlei ^{[13
]}

Liu, Xiaoming ^{[14
]}

Gu, Jun ^{[15
]}

Wang, Jinyan ^{[16
]}

Geng, Songmei ^{[17
]}

Liu, Quanzhong ^{[18
]}

Guo, Yifeng ^{[19
]}

Lv, Dong ^{[20
]}

Ren, Hong ^{[21
]}

Yang, Xiumin ^{[22
]}

Deng, Danqi ^{[23
]}

Li, Shanshan ^{[24
]}

Han, Xiuping ^{[25
]}

Biao, Zhenshu ^{[26
]}

Zheng, Min ^{[27
]}

Dong, Lichee ^{[28
]}

Su, Huijuan ^{[28
]}

Bai, Lili ^{[28
]}

O'Malley, John T. ^{[28
]}

Luo, Junxiang ^{[28
]}

Li, Yi ^{[28
]}

Wang, Min ^{[29
]}

Fan, Xinli ^{[29
]}

Zhang, Jianzhong ^{[1
]}

机构：

[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[2] Hangzhou First Peoples Hosp, Hangzhou, Peoples R China

[3] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China

[4] China Med Univ, Hosp 1, Shenyang, Peoples R China

[5] Wuxi Second Peoples Hosp, Wuxi, Jiangsu, Peoples R China

[6] Chinese Acad Med Sci, Hosp Skin Dis, Inst Dermatol, Nanjing, Peoples R China

[7] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[8] Fudan Univ, Huashan Hosp, Shanghai, Peoples R China

[9] Shanghai Skin Dis Hosp, Shanghai, Peoples R China

[10] Southwest Hosp AMU, Chongqing, Peoples R China

[11] Peking Univ First Hosp, Beijing, Peoples R China

[12] Jinan Cent Hosp, Jinan, Peoples R China

[13] Peking Univ Third Hosp, Beijing, Peoples R China

[14] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China

[15] Changhai Hosp Shanghai, Shanghai, Peoples R China

[16] Ningbo 2 Hosp, Ningbo, Peoples R China

[17] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China

[18] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China

[19] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai, Peoples R China

[20] Yancheng 1 Peoples Hosp, Yancheng, Peoples R China

[21] First Peoples Hosp Lianyungang, Lianyungang, Peoples R China

[22] CMU, Beijing Tongren Hosp, Beijing, Peoples R China

[23] Kunming Med Univ, Affiliated Hosp 2, Kunming, Yunnan, Peoples R China

[24] Jilin Univ, Hosp 1, Changchun, Peoples R China

[25] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[26] Peoples Hosp Liaoning Prov, Shenyang, Peoples R China

[27] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China

[28] Sanofi, Res & Dev, Shanghai, Peoples R China

[29] Sanofi China, Med, Shanghai, Peoples R China

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PT20

引用

页码：58 / 59

页数：2

共 50 条

[1] Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study
Zhao Yan
Wu LiMing
Lu QianJin
Gao XingHua
Zhu XiaoHong
Yao Xu
Li LinFeng
Li Wei
Ding YangFeng
Song ZhiQiang
Liu LingLing
Dang NingNing
Zhang ChunLei
Liu XiaoMing
Gu Jun
Wang JinYan
Geng SongMei
Liu QuanZhong
Guo YiFeng
Dong Li
Li Shelley
Xu Christine
OMalley John T
Laws Elizabeth
Amin Nikhil
Bansal Ashish
Wang Min
Zhang JianZhong
[J]. 国际皮肤性病学杂志（英文）., 2022, 05 (04)
[2] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
Zhao, Y.
Wu, L.
Lu, Q.
Gao, X.
Zhu, X.
Yao, X.
Li, L.
Li, W.
Ding, Y.
Song, Z.
Liu, L.
Dang, N.
Zhang, C.
Liu, X.
Gu, J.
Wang, J.
Geng, S.
Liu, Q.
Guo, Y.
Dong, L.
Su, H.
Bai, L.
O'Malley, J. T.
Luo, J.
Laws, E.
Mannent, L.
Ruddy, M.
Amin, N.
Bansal, A.
Ota, T.
Wang, M.
Zhang, J.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
[3] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Simpson, Eric L.
Merola, Joseph F.
Silverberg, Jonathan, I
Reich, Kristian
Warren, Richard B.
Staumont-Salle, Delphine
Girolomoni, Giampiero
Papp, Kim
de Bruin-Weller, Marjolein
Thyssen, Jacob P.
Zachariae, Rebecca
Olsen, Christiana K.
Wollenberg, Andreas
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
[4] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Tyring, Stephen K. K.
Rich, Phoebe
Tada, Yayoi
Beeck, Stefan
Messina, Izabella
Liu, Jie
Huang, Xiaohong
Shumack, Stephen
[J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
[5] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
[J]. Dermatology and Therapy, 2023, 13 : 595 - 608
[6] PHARMACOKINETICS OF DUPILUMAB IN PHASE III CONFIRMATORY STUDIES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.
Davis, J. D.
Rawal, S.
Paccaly, A.
Li, M.
Lai, C. -H.
Ardeleanu, M.
DiCioccio, A. T.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S61 - S61
[7] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
Ebisawa, Motohiro
Kataoka, Yoko
Tanaka, Akio
Nagao, Mizuho
Laws, Elizabeth
Mortensen, Eric
Nawata, Hisakatsu
Arima, Kazuhiko
Watanabe, Daisuke
Lu, Xin
Maloney, Jennifer
Dubost-Brama, Ariane
Bansal, Ashish
Yahata, Kenji
[J]. ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
[8] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Torrelo, A.
Rewerska, B.
Paller, Amy
Prakash, A.
Zhu, D.
Pontes, M.
Wu, Wen-Shuo
Eichenfield, Lawrence F.
Boecker, Ulrike
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
[9] Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Reich, Kristian
Thyssen, Jacob P.
Blauvelt, Andrew
Eyerich, Kilian
Soong, Weily
Rice, Zakiya P.
Hong, H. Chih-ho
Katoh, Norito
Valenzuela, Fernando
DiBonaventura, Marco
Bratt, Tamara A.
Zhang, Fan
Clibborn, Claire
Rojo, Ricardo
Valdez, Hernan
Kerkmann, Urs
[J]. LANCET, 2022, 400 (10348): : 273 - 282
[10] EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Zhao, Yan
Wu, Liming
Lu, Qianjin
Gao, Xinghua
Zhu, Xiaohong
Yao, Xu
Li, Linfeng
Li, Wei
Ding, Yangfeng
Song, Zhiqiang
Liu, Lingling
Dang, Ningning
Zhang, Chunlei
Liu, Xiaoming
Gu, Jun
Wang, Jinyan
Geng, Songhai
Liu, Qunazhong
Guo, Yifeng
Lv, Dong
Ren, Gong
Yang, Xiumin
Deng, Danqi
Li, Shanshan
Han, Xiuping
Biao, Shuzhen
Zheng, Min
Dong, Li
Su, Huijuan
Bai, Lili
O'Malley, John T.
Luo, Junxiang
Zhang, Jianzhong
[J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 58 - 58

← 1 2 3 4 5 →